This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Today's Health Winners and Losers

Shares of Valeant Pharmaceuticals (VRX - Get Report) were among the worst-performing health-related stocks Tuesday, slumping 15% after the drugmaker's phase III trial of a hepatitis C treatment failed to meet one of its key goals.

While the company's Viramidine drug fared well in overall safety compared to ribavirin, the study showed that it didn't meet an efficacy endpoint. The company said that the sustained viral response rate for Viramidine was 38% compared to 52% for ribavirin. "However," the company said, "the SVR rates were adversely impacted by the effect of lower dosing on a mg/kg basis in the Viramidine arm and by statistically inconsistent results seen in the rest of the world region." The company said it continues to work toward a commercial launch of the treatment, which is expected before the end of 2007. Shares were trading down $2.79 to $15.89.

Novavax (NVAX - Get Report) fell 8% after the company said it plans to sell 5.2 million shares of stock for $7.30 apiece, raising some $38 million. The sale price represents a 12% discount to Monday's closing price of $8.31. Novavax plans to use proceeds from the offering to fund general corporate needs. Rodman & Renshaw acted as the placement agent for the offering. Shares were trading down 64 cents to $7.67.

Shares of NitroMed (NTMD) rose 7% after the company announced the departure of its chief executive, Michael Loberg, and chief financial officer, Lawrence Bloch. The resignations are effective immediately. The drug company didn't offer an explanation for the departures, but the resignations come less than three weeks after NitroMed posted disappointing fourth-quarter results. Argeris Karabelas, the company's chairman, will assume the CEO position on an interim basis. Kenneth Bate, meanwhile, will become CFO as well as chief operating officer. Shares were trading up 54 cents to $8.37.

Biomet (BMET) fell 4% after the medical device company posted weaker-than-expected third-quarter revenue and offered tepid guidance. The company earned $106.1 million, or 43 cents a share, on revenue of $506.3 million. Analysts polled by Thomson First Call expected earnings of 43 cents a share and revenue of $516.3 million. During the year-earlier period, the company earned $96.8 million, or 38 cents a share, on revenue of $482 million. On an adjusted basis, the company earned $101.6 million, or 40 cents a share, a year earlier.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
GNBT $0.02 1.72%
JNJ $102.34 -0.85%
HWAY $22.29 -0.13%
NVAX $8.57 -3.92%
VRX $202.61 -0.36%


DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs